StreetAlpha
13F holdings · Q3 2026

Eversept Partners

New York, NY · files as Eversept Partners, LP
Know the moment Eversept Partners filesYou follow Eversept Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1697013

Eversept Partners reported 107 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (10.1%), EHC (7.6%) and ENSG (7.2%). Compared with Q2 2026, the fund opened new positions in GH, WAT and GRAL, added to UTHR, EHC and ENSG, trimmed NTRA, SNDX and CLDX and sold out of GSK, LLY and AMN.

Latest filing: what Eversept Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
22 new31 added47 trimmed30 sold outBought about $436M · sold about $420M
New 22
See all 22 →
Added 31
See all 31 →
Trimmed 47
See all 47 →
Sold out 30
See all 30 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.7B−5.4% vs last quarter · $1.9B including options
Stocks held10722 new · 30 sold out
Top 5 weight35.6%fairly concentrated
Turnover49%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
UTHR
United Therapeutics Corp Del
$176M10.1%325K+37K (+13%)8 of 8
2
EHC
Encompass Health Corp
$131M7.6%1.1M+55K (+5%)4 of 8
3
ENSG
Ensign Group Inc
$125M7.2%726K+124K (+21%)3 of 8
4
ABVX
Abivax SA
$109M6.3%1.1M+187K (+20%)5 of 8
5
VERA
Vera Therapeutics Inc
$76.3M4.4%2.4M+149K (+7%)8 of 8
6
RVTY
Revvity Inc
$68.8M4.0%450K+366K (+438%)8 of 8
7
NTRA
Natera Inc
$53M3.0%128K−48K (−27%)8 of 8
8
CTRE
Caretrust REIT Inc
$49.5M2.9%1.4M+281K (+26%)2 of 8
9
OHI
Omega Healthcare Invs Inc
$46.7M2.7%1M+525K (+109%)3 of 8
10
SNDX
Syndax Pharmaceuticals Inc
$45.9M2.6%2.4M−355K (−13%)8 of 8
🔒 97 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GSK
Gsk PLC ADR F
$25.3M482K
LLY
Eli Lilly & Co
$24.1M20K
AMN
Amn Healthcare Svcs Inc
$13.9M429K
CELC
Celcuity Inc
$13.4M128K
HUM
Humana Inc
$12.4M31K

🔒 Free account: see all 30.

Options

valued at the underlying shares
StockTypeValueSharesChange
QQQ
Invesco Qqq TR
Put$99.9M135K+36,400
SPY
Spdr S&P 500 ETF TR
Put$15.3M20K+20,000
TLT
Ishares TR
Put$7M90K+90,000
UHS
Universal Hlth Svcs Inc
Put$3.3M19K0

Reported value

last 8 quarters
$969MQ4 '24
$884MQ1 '25
$992MQ2 '25
$1.3BQ3 '25
$1.8BQ4 '25
$1.5BQ1 '26
$1.8BQ2 '26
$1.7BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Eversept Partners 13F FAQ

What does Eversept Partners own?

Eversept Partners reported 107 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (10.1%), EHC (7.6%) and ENSG (7.2%). The table above lists every position in the filing (the top 10 without an account).

What did Eversept Partners buy and sell in Q3 2026?

Compared with Q2 2026: 22 new positions, 31 added to, 47 trimmed and 30 sold out. New positions include GH, WAT and GRAL. It sold all of GSK, LLY and AMN.

When will Eversept Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Eversept Partners's portfolio worth?

The Q3 2026 filing reports $1.7B in US stocks ($1.9B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.